​

Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)

ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$289.17

52W Range

$200.63 - $377.46

50D Avg

$292.35

200D Avg

$298.39

Market Cap

$6.38B

Avg Vol (3M)

$329.86K

Beta

-1.08

Div Yield

-

MDGL Company Profile

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

528

IPO Date

Feb 06, 2007

Website

MDGL Performance

MDGL Financial Summary

Dec 24Dec 23Dec 22
Revenue$180.13M--
Operating Income$-497.88M$-380.50M$-293.57M
Net Income$-465.89M$-373.63M$-299.31M
EBITDA$-497.88M$-379.97M$-293.10M
Basic EPS$-21.90$-19.99$-17.47
Diluted EPS$-21.90$-19.99$-17.47

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 25May 01, 25 | 8:00 AM
Q4 24Feb 26, 25 | 8:00 AM
Q3 24Oct 31, 24 | 8:00 AM

Peer Comparison

TickerCompany
TERNTerns Pharmaceuticals, Inc.
VKTXViking Therapeutics, Inc.
APLSApellis Pharmaceuticals, Inc.
AKROAkero Therapeutics, Inc.